Inflammatory, Pericardial & Myocarditis

Inflammatory cardiac disease received its biggest guideline update in years with the ESC 2025 statements on myocarditis, pericarditis, and CV disease in pregnancy. Recurrent pericarditis has been transformed by IL-1 pathway inhibition — rilonacept (RHAPSODY) and anakinra are now first-line steroid-sparing therapy. The track covers immune-mediated and viral myocarditis (including post-COVID and post-vaccine cohorts), endomyocardial biopsy with the Updated Lake Louise CMR criteria, and modern infective endocarditis management with OPAT, the POET-derived oral step-down, and TEER for valvular destruction. Sessions also address cardiac sarcoidosis, eosinophilic and giant-cell myocarditis, and Chagas (PARACHUTE-HF).